📊 RNAC Key Takeaways
Is RNAC a Good Investment? Thesis Analysis
Cartesian Therapeutics exhibits acute financial distress with negative stockholders equity of -$126.2M and catastrophic operating losses of -$143.4M on minimal $2.8M revenue, indicating technical insolvency. While 599% YoY revenue growth signals early-stage product commercialization, the $73.9M annual operating cash burn rate will deplete the $125.1M cash position within 18-24 months absent capital restructuring or dramatic operational improvement, creating imminent solvency risk.
Why Buy RNAC? Key Strengths
- Exceptional 599% YoY revenue growth suggests early-stage product commercialization and market acceptance
- Adequate cash position of $125.1M provides near-term operational funding capacity
- Strong liquidity ratios (Current Ratio 8.65x, Quick Ratio 8.65x) provide working capital flexibility
RNAC Investment Risks to Consider
- Negative stockholders equity of -$126.2M represents technical insolvency on book value basis
- Unsustainable operating cash burn of -$73.9M annually with limited 18-24 month runway at current burn rates
- Operating losses of -$143.4M against $2.8M revenue demonstrate extreme unit economics with no visible path to profitability
- Liabilities of $422.7M exceed assets of $296.4M, creating substantial creditor and dilution risk
Key Metrics to Watch
- Monthly cash burn rate and remaining runway timeline
- Gross margin realization as revenue scales and manufacturing efficiency improves
- Achievement of clinical/regulatory milestones required for revenue growth acceleration
RNAC Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 8.65x current ratio provides a solid financial cushion.
RNAC Profitability Ratios
RNAC vs Healthcare Sector
How Cartesian Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is RNAC Overvalued or Undervalued?
Based on fundamental analysis, Cartesian Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
RNAC Balance Sheet & Liquidity
RNAC 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Cartesian Therapeutics, Inc.'s revenue has declined by 55% over the 5-year period, indicating business contraction. The most recent EPS of $-4.49 indicates the company is currently unprofitable.
RNAC Growth Metrics (YoY)
RNAC Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | $13.8M | $-1.13 |
| Q2 2025 | N/A | -$1.8M | $-0.07 |
| Q1 2025 | $400.0K | -$17.7M | $-0.68 |
| Q3 2024 | N/A | -$9.0M | $-1.13 |
| Q2 2024 | $5.2M | -$11.4M | $0.54 |
| Q1 2024 | $5.8M | -$21.7M | $-4.24 |
| Q3 2023 | $6.6M | -$7.9M | $-0.05 |
| Q2 2023 | $5.2M | $8.6M | $0.06 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
RNAC Capital Allocation
RNAC SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Cartesian Therapeutics, Inc. (CIK: 0001453687)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RNAC
What is the AI rating for RNAC?
Cartesian Therapeutics, Inc. (RNAC) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are RNAC's key strengths?
Claude: Exceptional 599% YoY revenue growth suggests early-stage product commercialization and market acceptance. Adequate cash position of $125.1M provides near-term operational funding capacity.
What are the risks of investing in RNAC?
Claude: Negative stockholders equity of -$126.2M represents technical insolvency on book value basis. Unsustainable operating cash burn of -$73.9M annually with limited 18-24 month runway at current burn rates.
What is RNAC's revenue and growth?
Cartesian Therapeutics, Inc. reported revenue of $2.8M.
Does RNAC pay dividends?
Cartesian Therapeutics, Inc. does not currently pay dividends.
Where can I find RNAC SEC filings?
Official SEC filings for Cartesian Therapeutics, Inc. (CIK: 0001453687) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RNAC's EPS?
Cartesian Therapeutics, Inc. has a diluted EPS of $-5.02.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RNAC a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Cartesian Therapeutics, Inc. has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RNAC stock overvalued or undervalued?
Valuation metrics for RNAC: ROE of N/A (sector avg: 15%), net margin of -4,658.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy RNAC stock in 2026?
Our dual AI analysis gives Cartesian Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RNAC's free cash flow?
Cartesian Therapeutics, Inc.'s operating cash flow is $-73.9M, with capital expenditures of $5.5M. FCF margin is -2,838.6%.
How does RNAC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -4,658.6% (avg: 12%), ROE N/A (avg: 15%), current ratio 8.65 (avg: 2).